Dr. Mark Rigby is a pediatric physician scientist who currently is an associate professor at Indiana University School of Medicine. He completed his medical degree and doctor of philosophy in diabetes immunology at the University of Massachusetts. He conducted postgraduate clinical training in pediatrics and pediatric critical care at the Johns Hopkins Hospital. In addition to conducting basic and clinical research in Type 1 diabetes, he is the academic chief of pediatric critical care at Riley Hospital for Children in Indianapolis. He has a significant interest in evaluating how novel immune therapies may assist in inducing immune tolerance in Type 1 diabetes. He is now the protocol chair of an ongoing NIH-sponsored clinical trial using alefacept (a biologic agent that targets memory cells to prevent ongoing beta cell loss and stabilize disease in newly diagnosed Type 1 diabetes.